Nilotinib and dasatinib—new 'magic bullets' for CML? (original) (raw)

Hematology

Nature Reviews Clinical Oncology volume 7, pages 557–558 (2010)Cite this article

Subjects

The efficacy of nilotinib and dasatinib as frontline treatment of chronic myeloid leukemia has been documented in small phase II studies. Now, two clinical trials have assessed the effectiveness of second-generation tyrosine kinase inhibitors in comparison with standard dose imatinib at 1 year. Will these results change our current practice?

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Deininger, M. et al. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. Blood 114, a1126 (2009).
    Google Scholar
  2. Marin, D. et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112, 4437–4444 (2008).
    Article CAS PubMed PubMed Central Google Scholar
  3. Cortes, J. E. et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular endpoints: tyrosine kinase inhibitor optimization and selectivity study. J. Clin. Oncol. 28, 424–430 (2010).
    Article CAS PubMed Google Scholar
  4. Shah, N. P. et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and intolerant chronic phase chronic myeloid leukemia. J. Clin. Oncol. 26, 3204–3212 (2008).
    Article CAS PubMed Google Scholar
  5. Kantarjian, H. M. et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase following imatinib resistance and intolerance. Blood 110, 3540–3546 (2007).
    Article CAS PubMed Google Scholar
  6. Rosti, G. et al Nilotinib for the frontline treatment of Ph+ chronic myeloid leukaemia. Blood 114, 4933–4938 (2009).
    Article CAS PubMed Google Scholar
  7. Cortes, J. E. et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukaemia. J. Clin. Oncol. 28, 398–404 (2010).
    Article CAS PubMed Google Scholar
  8. Saglio, G. et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukaemia. N. Engl. J. Med. 362, 2251–2259 (2010).
    Article CAS PubMed Google Scholar
  9. Kantarjian, H. M. et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia. N. Engl. J. Med. 362, 2260–2270 (2010).
    Article CAS PubMed Google Scholar
  10. Baccarani, M. et al. Chronic myeloid leukaemia: an update of concepts and management recommendations of European LeukemiaNet. J. Clin. Oncol. 27, 6041–6051 (2009).
    Article CAS PubMed PubMed Central Google Scholar

Download references

Author information

Authors and Affiliations

  1. Department of Cellular Biotechnologies and Hematology, Sapienza University, Via Benevento 6, 00161, Rome, Italy
    Massimo Breccia

Authors

  1. Massimo Breccia
    You can also search for this author inPubMed Google Scholar

Ethics declarations

Competing interests

M. Brecchia declares he is a consultant for Novartis and is on the speaker's bureau for Bristol–Myers Squibb.

Rights and permissions

About this article

Cite this article

Breccia, M. Nilotinib and dasatinib—new 'magic bullets' for CML?.Nat Rev Clin Oncol 7, 557–558 (2010). https://doi.org/10.1038/nrclinonc.2010.151

Download citation

This article is cited by